logo-mobile
  • About
    ▼
    • Mission
    • Technology
    • Team
    • Investors
    • Legal
  • Technology
    ▼
    • Technology Story
    • How It Works
    • Targeted Impact
    • Applications
  • Pipeline
    ▼
    • Development
    • Pipeline Objectives
    • Featured Publications
  • News
    ▼
    • Press Releases
    • Media Coverage
    • Events
  • Logo
  • Partners
  • Careers
    ▼
    • Open Positions
  • Contact
  • Search
  • About
    • Mission
    • Technology
    • Team
    • Investors
    • Legal
  • Technology
    • Technology Story
    • How It Works
    • Targeted Impact
    • Applications
  • Pipeline
    • Development
    • Pipeline Objectives
    • Featured Publications
  • News
    • Press Releases
    • Media Coverage
    • Events
  • Logo
  • Partners
  • Careers
    • Open Positions
  • Contact
  • Search

how can we help?

Cybrexa Therapeutics to Present at the 2019 BIO International Convention

New Haven, Conn., May 8, 2019 – Cybrexa Therapeutics, a biotechnology company developing a new class of cancer therapeutics through its alphalex™ tumor targeting platform, today announced that Per Hellsund, President and Chief Executive Officer of the Company, will present at the 2019 BIO International Convention being held on June 3-6, 2019 at the Pennsylvania Convention Center in Philadelphia, PA.

Mr. Hellsund will present a corporate overview on the Company’s platform, pipeline, and lead candidate CBX-11 (alphalexTM-rucaparib)

Details for the presentation are below:

Event: 2019 BIO International Convention

Date: Monday, June 3, 2019

Time: 2:45 pm ET

Location: Pennsylvania Convention Center, Theatre 4

 

Members of the management team will be available for meetings at the BIO International Convention in Philadelphia. To arrange a meeting with management, please contact Janhavi Mohite at [email protected] or visit the BIO One-on-One Partnering webpage to schedule a meeting directly.

 

About the alphalex™ Technology Platform

 

The Cybrexa alphalex™ technology platform enables the delivery of small molecules across the cell membrane under low pH conditions, which is a universal feature of cancer cells. As a result, alphalex™ technology – which consists of a novel peptide, linker and small molecule anti-cancer agent – allows for antigen-independent, intracellular delivery of small molecule anti-cancer agents directly into the tumor cell. View a video of the mechanism of action of the technology at https://www.cybrexa.com/our-technology/.

 

About Cybrexa

 

Cybrexa is a privately-held biotechnology company dedicated to developing an entirely new class of cancer therapies using its alphalex™ platform to deliver anti-cancer agents directly into tumor cells. The Company’s lead candidate, CBX-11 (alphalex™-rucaparib), is in preclinical development with advancing plans to initiate clinical development by 1Q 2020. Cybrexa was founded by physician-scientists, and has an experienced management team that has built numerous successful life sciences companies and raised hundreds of millions of dollars in venture capital. For more information about Cybrexa, please visit www.cybrexa.com.

 Contacts

Media Relations

[email protected]

Post navigation

Previous PostPrevious Cybrexa Therapeutics Unveils Rucaparib as FDA- and EMA-Approved PARP Inhibitor in Lead Candidate CBX-11, Which Demonstrates Synergistic Efficacy with Chemotherapy Without Compounded Toxicity
Next PostNext Cybrexa Therapeutics’ Preclinical Data Demonstrate its alphalex™ Platform Enables Tumor Targeting of Multiple PARP Inhibitors, Effectively Inducing Significant Tumor Cell Killing When Combined with Chemotherapy

Recent Comments

    Archives

    Categories

    • Board of directors
    • Management Team
    • Scientific Advisors

    Meta

    • Log in
    • Entries feed
    • Comments feed
    • WordPress.org

    about

    about

    • Mission
    • technology
    • team

    Technology

    Technology

    • technology story
    • targeted impact
    • how it works
    • applications

    pipeline

    pipeline

    • Development
    • Pipeline Objectives
    • Featured Publications

    news

    news

    • press releases
    • media coverage
    • events

    partners

    partners

    careers

    careers

    • open positions

    Contact us

    • legal

    © 2018 Cybrexa | All Rights Reserved